News1 min ago
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
The primary efficacy endpoint of PARADIGM, (NCT05357950), is the assessment of ALS-biomarkers to evaluate PrimeC and its biological activity. Secondary endpoints include the clinical outcome measures...
